Downloads: 4 | Views: 400 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2
Masters Thesis | Health and Medical Sciences | India | Volume 12 Issue 8, August 2023 | Popularity: 5.3 / 10
Study of Adverse Effects and Outcome of All Oral Longer Regimen for Drug - Resistant Tuberculosis at Nodal DRTB Center, S N M C, Agra
Manoj Kumar Pippal, Santosh Kumar, Gajendra Vikram Singh, Sachin Kumar Gupta
Abstract: Introduction and Background: TB was the leading cause of death from a single infectious agent, ranking above HIV/AIDS until the coronavirus (COVID - 19) pandemic. In 2021, the estimated proportion of people with TB who had MDR/RR - TB was 3.6% among new cases and 18% among those previously treated. India is one of the nations in the world which has the highest burden of Multidrug - resistant tuberculosis (26%). The estimated number of MDR/RR - TB cases in India is 124000 (9.1/lakh population). A total of 109 countries were using all - oral longer regimens for the treatment of MDR/RR - TB. Material and Methods: The present study is a hospital - based observational prospective non - randomized without a control group, which was performed at a nodal DRTB center, Department of Tuberculosis & Respiratory Diseases, S. N. Medical College Agra. Results: 140 patients were enrolled on the All - Oral Longer regimen after obtaining informed consent. Among 140 patients 75.6%, 77.6%, 82.4%, 82.4%, and 80.2% were culture negative at the end of 3rd, 6th, 9th, 12th and 18th months respectively. The most common adverse event observed in this group of patients was Dermatological events which accounts for 29.2% followed by nervous system (17.8%) and gastrointestinal (15%) events. Among the study population 80.2% (112) were culture negative at the end of treatment, 5.6% died, 7.8% lost to follow up and 6.4% failed. Conclusions: Patients on the All Oral Longer regimen for DRTB have higher and more rapid sputum culture conversion rate, lower mortality, and fewer adverse events which are manageable, which indicates that the All Oral Longer regimen was well tolerated with better compliance in comparison to previous treatment regimens for DRTB.
Keywords: drug - resistant tuberculosis; extensively drug - resistant tuberculosis; national tuberculosis elimination program; AOLR, PMDT
Edition: Volume 12 Issue 8, August 2023
Pages: 515 - 520
DOI: https://www.doi.org/10.21275/SR23802200839
Make Sure to Disable the Pop-Up Blocker of Web Browser